Lantheus Holdings, Inc. filings document its radiopharmaceutical operating results, Nasdaq-listed common stock, governance and material corporate events. Form 8-K reports furnish quarterly and annual financial results, business updates, FDA-related disclosures for diagnostic and therapeutic radiopharmaceutical products, share repurchase authorization, and executive and board changes.
Proxy materials describe director elections, executive compensation, shareholder voting matters and equity incentive plan approvals. The filings also cover material modifications to security holder rights, Regulation FD disclosures and capital-structure details relevant to common stock issued by a public radiopharmaceutical company.
The Vanguard Group filed Amendment No. 8 to Schedule 13G/A reporting zero beneficial ownership of Lantheus Holdings Inc. common stock. The filing states Amount beneficially owned: 0 and Percent of class: 0%. It explains an internal realignment on January 12, 2026 that caused certain Vanguard subsidiaries to report holdings separately.
Lantheus Holdings, Inc. calls its 2026 Annual Meeting of Shareholders for April 30, 2026, asking investors to elect four Class II directors and approve several governance and compensation matters. The board recommends voting for all director nominees, for say‑on‑pay, and for annual future say‑on‑pay votes.
Shareholders are also asked to approve declassifying the board over time, a refreshed 2026 equity incentive plan, and ratification of Deloitte & Touche as auditor. The proxy details a largely independent, skills‑diverse board, strong governance policies, and an executive pay program tied to strategic and operational performance.
The company highlights 2025 strategic moves, including acquiring Life Molecular Imaging and Evergreen Theragnostics, divesting its legacy SPECT business, and advancing a late‑stage radiodiagnostic pipeline with multiple FDA milestones in 2026 across prostate cancer, neuroendocrine tumors, and Alzheimer’s disease imaging.
Lantheus Holdings is soliciting votes for its 2026 Annual Meeting and outlines strategic, operational and governance priorities while reporting key portfolio moves and regulatory milestones. The company says its products impacted ~7M patients in 2025 and highlights two acquisitions—Life Molecular Imaging (now Lantheus Biosciences) and Evergreen Theragnostics—plus the divestiture of its legacy SPECT business, effective January 1, 2026.
The proxy notes commercial momentum for PYLARIFY and Neuraceq, and lists near-term regulatory milestones: PYLARIFY TruVu FDA approval in March (day redacted) with a regionally phased launch beginning in 4Q 2026; PNT2003 received tentative ANDA approval in February 2026; OCTEVY has a PDUFA date of March 29; and MK6240 has a PDUFA date of August 13. The Board is conducting a CEO search; Mary Anne Heino is Executive Chairperson and Interim CEO.
Lantheus Holdings, Inc. officer Daniel Niedzwiecki received an equity award of 36,692 shares of common stock on March 5, 2026 at a stated price of $0.00 per share. This consists of 18,346 restricted stock units that vest in equal installments over three years and 18,346 performance-based PSUs that cliff vest after a three-year performance period, with the final PSU amount adjustable between 0% and 200% of target based on performance. On the same date, 1,283 shares were disposed of at $76.31 per share to cover taxes, leaving him with 119,376 shares of common stock held directly following these transactions.
Dinkelborg Ludger reported acquisition or exercise transactions in this Form 4 filing.
Lantheus Holdings executive Ludger Dinkelborg received an equity award of 20,966 shares of common stock on March 5, 2026 at no purchase cost. After this grant, his directly held common stock totaled 35,731 shares.
The award consists of 10,483 restricted stock units that vest in equal installments over three years and 10,483 Total Shareholder Return performance-based restricted stock units that cliff vest after a three-year performance period. The performance-based units can ultimately settle at 0% to 200% of the target amount depending on results.
Lantheus Holdings CFO Robert J. Marshall Jr. reported equity awards and related tax withholding in company stock. He acquired 38,002 shares of common stock on March 5, 2026 at a stated price of $0.00 per share as a grant or award.
The award consists of 19,001 restricted stock units that vest in equal installments over three years and 19,001 Total Shareholder Return performance-based restricted stock units that cliff vest after a three-year performance period, with the final PSU award ranging from 0% to 200% of the target. On the same date, 1,182 shares were disposed of at $76.31 per share to cover tax obligations, leaving him with 122,792 directly owned shares of common stock after these transactions.
Lantheus Holdings, Inc. Chief Accounting Officer Kimberly Brown reported equity compensation and a related tax-withholding transaction in common stock. On March 5, 2026, she acquired 6,158 shares at $0.00 per share as a grant, consisting of 3,079 restricted stock units vesting over three years and 3,079 performance-based PSUs that cliff vest after a three-year performance period, with the final PSU amount ranging from 0% to 200% of target based on results. On the same date, 133 shares were disposed of at $76.31 per share for tax withholding. Following these transactions, she directly owned 13,726 common shares.
Lantheus Holdings, Inc. Chief Commercial Officer Amanda Michelle Morgan reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 26,208 shares at no cost, consisting of 13,104 restricted stock units and 13,104 performance-based PSUs that vest over a three-year period.
The Form 4 also shows a disposition of 595 shares at $76.31 per share to satisfy tax obligations through share withholding, not an open-market sale. After these transactions, she directly holds 64,153 shares of Lantheus common stock.
Lantheus Holdings, Inc. reported that officer Daniel Niedzwiecki received 5,169 shares of common stock on March 2, 2026 at no cost, reflecting additional shares from performance-based PSUs that vested above target. On the same date, 8,259 shares were disposed of at $76.30 per share to cover tax obligations, leaving him with 83,967 directly held shares.